Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Change in Accured Expenses (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Change in Accured Expenses for 16 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 107.8% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, up 6.4% year-over-year, with the annual reading at $2.0 million for FY2025, 6.4% up from the prior year.
  • Change in Accured Expenses hit $1.0 million in Q4 2025 for Perspective Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $15.7 million in Q3 2024 to a low of -$13.0 million in Q4 2024.
  • Historically, Change in Accured Expenses has averaged $403000.0 across 5 years, with a median of $333000.0 in 2021.
  • Biggest five-year swings in Change in Accured Expenses: surged 76400.0% in 2022 and later plummeted 87080.0% in 2024.
  • Year by year, Change in Accured Expenses stood at $95000.0 in 2021, then surged by 503.16% to $573000.0 in 2022, then tumbled by 97.38% to $15000.0 in 2023, then tumbled by 87080.0% to -$13.0 million in 2024, then surged by 107.8% to $1.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CATX at $1.0 million in Q4 2025, $1.4 million in Q3 2025, and $2.1 million in Q2 2025.